Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Not all stage III endometrial cancer patients benefit equally from immunotherapy after surgery. New guidance emphasizes that molecular subtype — particularly DNA mismatch repair status — should drive the decision to add a PD-1 inhibitor to chemotherapy. Patients with dMMR tumors show clear benefit, while those with pMMR tumors do not, making routine immunotherapy addition unjustified in the latter group.
When it comes to treating surgically resected stage III endometrioid endometrial cancer, one size definitely does not fit all. Experts from Brigham and Women's Hospital are calling for molecular profiling to be the cornerstone of adjuvant treatment decisions — specifically, whether to add a PD-1 inhibitor to standard carboplatin and paclitaxel chemotherapy.
The key dividing line is DNA mismatch repair (MMR) status. For patients with deficient MMR (dMMR) or MSI-H tumors, evidence from the KEYNOTE-B21 trial — designed specifically for fully resected stage III–IVA patients with no residual disease — supports adding pembrolizumab to chemotherapy. The RUBY trial adds further backing for dMMR patients with stage IIIC2 disease. By contrast, patients with proficient MMR (pMMR) tumors showed no consistent benefit, and the lower tumor mutational burden in this group may mean complete surgical resection actually reduces any potential immunotherapy effect.
Key Takeaways:
Why it matters: With immunotherapy carrying real risks — including immune-related adverse events and hepatotoxicity — adding it without clear molecular justification could harm patients more than help them. Precision-guided treatment is the path forward.
